Show simple item record

Interleukin inhibitors and the associated risk of candidiasis

dc.contributor.authorSabir Khan
dc.contributor.authorHazrat Bilal
dc.contributor.authorMuhammad Nadeem Khan
dc.contributor.authorWenjie Fang
dc.contributor.authorWenqiang Chang
dc.contributor.authorBin Yin
dc.contributor.authorNing-jing Song
dc.contributor.authorZhongrong Liu
dc.contributor.authorDongxing Zhang
dc.contributor.authorDongxing Zhang
dc.contributor.authorFen Yao
dc.contributor.authorXun Wang
dc.contributor.authorQian Wang
dc.contributor.authorLin Cai
dc.contributor.authorBing Hou
dc.contributor.authorJiayue Wang
dc.contributor.authorChunyan Mao
dc.contributor.authorLingxi Liu
dc.contributor.authorYuebin Zeng
dc.contributor.authorYuebin Zeng
dc.contributor.otherDepartment of Dermatology, The Second Affiliated Hospital of Shantou University Medical College, Shantou, Guangdong, China
dc.contributor.otherDepartment of Dermatology, The Second Affiliated Hospital of Shantou University Medical College, Shantou, Guangdong, China
dc.contributor.otherDepartment of Microbiology, Faculty of Biological Sciences, Quaid-I-Azam University, Islamabad, Pakistan
dc.contributor.otherDepartment of Dermatology, Changzheng Hospital, Second Military Medical University, Shanghai, China
dc.contributor.otherSchool of Pharmacy, Shandong University, Qingdao, Shandong, China
dc.contributor.otherDepartment of Dermatovenereology, Chengdu Second People’s Hospital, Chengdu, China
dc.contributor.otherDepartment of Dermatology, Tongren Hospital, Shanghai Jiao Tong University, School of Medicine, Shanghai, China
dc.contributor.otherDepartment of Dermatology, First Affiliated Hospital of Guangzhou Medical University, Guangzhou, Guangdong, China
dc.contributor.otherDepartment of Dermatology, Meizhou Dongshan Hospital, Meizhou, Guangdong, China
dc.contributor.otherDepartment of Dermatology, Meizhou People’s Hospital, Meizhou, Guangdong, China
dc.contributor.other0Department of Pharmacy, Shantou University School Medical College, Shantou, China
dc.contributor.otherDepartment of Dermatology, The Second Affiliated Hospital of Shantou University Medical College, Shantou, Guangdong, China
dc.contributor.otherDepartment of Dermatology, The Second Affiliated Hospital of Shantou University Medical College, Shantou, Guangdong, China
dc.contributor.otherDepartment of Dermatology, The Second Affiliated Hospital of Shantou University Medical College, Shantou, Guangdong, China
dc.contributor.other1Department of Clinical Laboratory, Skin and Venereal Diseases Prevention and Control Hospital of Shantou City, Shantou, Guangdong, China
dc.contributor.other2Department of Dermatology, West China Second University Hospital, Sichuan University, Chengdu, Sichuan, China
dc.contributor.other2Department of Dermatology, West China Second University Hospital, Sichuan University, Chengdu, Sichuan, China
dc.contributor.other2Department of Dermatology, West China Second University Hospital, Sichuan University, Chengdu, Sichuan, China
dc.contributor.otherDepartment of Dermatology, The Second Affiliated Hospital of Shantou University Medical College, Shantou, Guangdong, China
dc.contributor.other2Department of Dermatology, West China Second University Hospital, Sichuan University, Chengdu, Sichuan, China
dc.date.accessioned2025-10-09T05:32:17Z
dc.date.available2025-10-09T05:32:17Z
dc.date.issued01-03-2024
dc.identifier.urihttps://www.frontiersin.org/articles/10.3389/fimmu.2024.1372693/full
dc.identifier.urihttp://digilib.fisipol.ugm.ac.id/repo/handle/15717717/41140
dc.description.abstractInterleukins (ILs) are vital in regulating the immune system, enabling to combat fungal diseases like candidiasis effectively. Their inhibition may cause enhanced susceptibility to infection. IL inhibitors have been employed to control autoimmune diseases and inhibitors of IL-17 and IL-23, for example, have been associated with an elevated risk of Candida infection. Thus, applying IL inhibitors might impact an individual’s susceptibility to Candida infections. Variations in the severity of Candida infections have been observed between individuals with different IL inhibitors, necessitating careful consideration of their specific risk profiles. IL-1 inhibitors (anakinra, canakinumab, and rilonacept), IL-2 inhibitors (daclizumab, and basiliximab), and IL-4 inhibitors (dupilumab) have rarely been associated with Candida infection. In contrast, tocilizumab, an inhibitor of IL-6, has demonstrated an elevated risk in the context of coronavirus disease 2019 (COVID-19) treatment, as evidenced by a 6.9% prevalence of candidemia among patients using the drug. Furthermore, the incidence of Candida infections appeared to be higher in patients exposed to IL-17 inhibitors than in those exposed to IL-23 inhibitors. Therefore, healthcare practitioners must maintain awareness of the risk of candidiasis associated with using of IL inhibitors before prescribing them. Future prospective studies need to exhaustively investigate candidiasis and its associated risk factors in patients receiving IL inhibitors. Implementing enduring surveillance methods is crucial to ensure IL inhibitors safe and efficient utilization of in clinical settings.
dc.language.isoEN
dc.publisherFrontiers Media S.A.
dc.subject.lccImmunologic diseases. Allergy
dc.titleInterleukin inhibitors and the associated risk of candidiasis
dc.typeArticle
dc.description.keywordsinterleukins (ILs)
dc.description.keywordsimmune system
dc.description.keywordssignaling pathways
dc.description.keywordsinterleukin inhibitors
dc.description.keywordscandidiasis
dc.description.doi10.3389/fimmu.2024.1372693
dc.title.journalFrontiers in Immunology
dc.identifier.e-issn1664-3224
dc.identifier.oaioai:doaj.org/journal:ad30090d669449f89c765dc2edec669b


This item appears in the following Collection(s)

Show simple item record